Long-term data, released in April 2009 from a phase III clinical trial of men with advanced prostate cancer, show overall survival was increased with the use of an anti-cancer vaccine. This is big news not only for men with advanced prostate cancer, but it also gives hope that cancer vaccines can be effective against other advanced cancers. By harnessing a patient's own immune system to fight the cancer, cancer vaccines take a novel approach against these otherwise fatal conditions. The day the news broke, Patient Power conducted a ‘Breaking News’ interview with Vanderbilt University Medical Center Urologic Oncologist Dr. Sam Chang to put the information in perspective.
Dr. Chang helps listeners to understand what this news potentially means for men with advanced prostate cancer. He explains the details of the trial and how this affects FDA approval of Provenge. Dr. Chang then goes on to talk about how cancer vaccines can provide an advantage through individualized therapy. To learn more, listen to this enlightening program with Dr. Sam Chang.
Sam S. Chang, M.D.
Associate Professor of Urologic Surgery , Vanderbilt Medical CenterDr. Chang is a noted researcher in the treatment of prostate, bladder and renal cancer. He is on the editorial boards of several scientific journals, and has authored more than 150 publications. He received his undergraduate degree from Princeton University and his medical degree from Vanderbilt University. He was a urologic oncology fellow at Memorial Sloan-Kettering Cancer Center in New... more >